Quantbot Technologies LP Buys 42,419 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

Quantbot Technologies LP grew its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 342.0% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 54,822 shares of the company’s stock after purchasing an additional 42,419 shares during the quarter. Quantbot Technologies LP’s holdings in Henry Schein were worth $3,997,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in HSIC. Cromwell Holdings LLC raised its holdings in Henry Schein by 93.4% in the 3rd quarter. Cromwell Holdings LLC now owns 352 shares of the company’s stock worth $26,000 after purchasing an additional 170 shares in the last quarter. Summit Securities Group LLC bought a new position in Henry Schein in the 2nd quarter worth $31,000. Beach Investment Counsel Inc. PA purchased a new stake in shares of Henry Schein in the 2nd quarter worth about $37,000. Blue Trust Inc. grew its position in shares of Henry Schein by 104.2% in the 2nd quarter. Blue Trust Inc. now owns 931 shares of the company’s stock worth $60,000 after buying an additional 475 shares during the period. Finally, Farther Finance Advisors LLC grew its position in shares of Henry Schein by 58.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 933 shares of the company’s stock worth $68,000 after buying an additional 346 shares during the period. 96.62% of the stock is currently owned by institutional investors.

Insider Activity

In other news, SVP Lorelei Mcglynn sold 21,035 shares of the stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $69.30, for a total value of $1,457,725.50. Following the transaction, the senior vice president now owns 71,833 shares in the company, valued at $4,978,026.90. This represents a 22.65 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Michael S. Ettinger sold 12,240 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $75.00, for a total transaction of $918,000.00. Following the completion of the transaction, the chief operating officer now owns 87,706 shares in the company, valued at $6,577,950. This trade represents a 12.25 % decrease in their position. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.

Henry Schein Stock Performance

Shares of HSIC stock opened at $77.28 on Wednesday. Henry Schein, Inc. has a one year low of $63.67 and a one year high of $82.63. The company’s 50-day moving average is $71.03 and its 200 day moving average is $69.76. The company has a market capitalization of $9.64 billion, a price-to-earnings ratio of 31.80, a price-to-earnings-growth ratio of 2.20 and a beta of 0.87. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, November 5th. The company reported $1.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.17 by $0.05. The firm had revenue of $3.17 billion for the quarter, compared to the consensus estimate of $3.24 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The business’s quarterly revenue was up .4% compared to the same quarter last year. During the same quarter last year, the firm posted $1.32 EPS. Sell-side analysts expect that Henry Schein, Inc. will post 4.78 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on HSIC shares. UBS Group reduced their target price on shares of Henry Schein from $75.00 to $72.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th. JPMorgan Chase & Co. reduced their target price on shares of Henry Schein from $88.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. Barrington Research reaffirmed an “outperform” rating and issued a $82.00 target price on shares of Henry Schein in a research report on Wednesday, November 6th. Robert W. Baird reduced their target price on shares of Henry Schein from $92.00 to $82.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. Finally, Evercore ISI upped their target price on shares of Henry Schein from $70.00 to $74.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 8th. Six analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Henry Schein presently has a consensus rating of “Moderate Buy” and an average target price of $78.89.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.